TY  - GEN
AU  - Parra-Guillen,Zinnia P
AU  - Berger,Peter B
AU  - Haschke,Manuel
AU  - Donzelli,Massimiliano
AU  - Winogradova,Daria
AU  - Pfister,Bogumila
AU  - Früh,Martin
AU  - Gillessen,Silke
AU  - Krähenbühl,Stephan
AU  - Kloft,Charlotte
AU  - Joerger,Markus
TI  - Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment
SN  - 1742-7843
PY  - 2018///0130
KW  - Aged
KW  - Antineoplastic Agents
KW  - adverse effects
KW  - Caffeine
KW  - pharmacokinetics
KW  - Carcinoma, Non-Small-Cell Lung
KW  - drug therapy
KW  - Chromatography, Liquid
KW  - Cytochrome P-450 CYP1A2
KW  - genetics
KW  - Cytochrome P-450 CYP3A
KW  - Dried Blood Spot Testing
KW  - Drug Monitoring
KW  - methods
KW  - Erlotinib Hydrochloride
KW  - Female
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Midazolam
KW  - Middle Aged
KW  - Models, Biological
KW  - Pharmacogenetics
KW  - Pharmacogenomic Variants
KW  - Phenotype
KW  - Prospective Studies
KW  - Protein Kinase Inhibitors
KW  - Substrate Specificity
KW  - Tandem Mass Spectrometry
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial; Journal Article
UR  - https://doi.org/10.1111/bcpt.12801
ER  -